Anti–PD-L1 Treatment Induced Central Diabetes Insipidus

CONTEXT: Immune checkpoint inhibitors, including anti–programmed cell death protein 1 (PD-1), anti–programmed cell death protein ligand 1 (PD-L1), and anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) monoclonal antibodies, have been widely used in cancer treatment. They are known to cause immune-r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Endocrinol Metab
Main Authors: Zhao, Chen, Tella, Sri Harsha, Del Rivero, Jaydira, Kommalapati, Anuhya, Ebenuwa, Ifechukwude, Gulley, James, Strauss, Julius, Brownell, Isaac
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2017
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800826/
https://ncbi.nlm.nih.gov/pubmed/29220526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2017-01905
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados